153 results on '"Uy, Geoffrey L."'
Search Results
2. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
3. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
4. Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?
5. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
6. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
7. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes
8. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
9. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis
10. Machine learning–based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors
11. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
12. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
13. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS
14. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
15. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
16. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia
17. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
18. CD123 bi-specific antibodies in development in AML: What do we know so far?
19. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
20. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
21. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
22. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
23. Clinical and functional significance of circular RNAs in cytogenetically normal AML
24. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)
25. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
26. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
27. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
28. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
29. Choosing induction chemotherapy in therapy-related acute myeloid leukemia
30. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
31. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
32. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma
33. Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation
34. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
35. T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia
36. Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated
37. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
38. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
39. Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform
40. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia
41. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
42. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
43. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
44. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
45. Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
46. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
47. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
48. Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials.
49. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
50. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.